Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanamivir - Vaxart/GlaxoSmithKline

Drug Profile

Zanamivir - Vaxart/GlaxoSmithKline

Alternative Names: 4-guanidino Neu5Ac2en; Dectova; GG 167; GR 121167; GR-121167X; Relenza

Latest Information Update: 06 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biota Holdings; Monash University
  • Developer GlaxoSmithKline
  • Class Antivirals; Guanidines; Pyrans; Sialic acids
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Mar 2019 Preregistration for Influenza virus infections (In adolescents, In adults, In children, In infants) in European Union (IV), prior to March 2019
  • 01 Mar 2019 The Committee for Medicinal Products for Human Use (CHMP) recommends marketing authorisation for intravenous zanamivir for Influenza virus infections in the European Union
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top